Evidence map›Paper›PMID 42440000›Full record

ReviewPharmaceutical medicine2026

Medical Affairs in the Age of Complexity: From Scientific Support to Strategic Enterprise Integrator.

Mussa Arvani

Abstract readReview
PubMed Publisher
In one paragraph

Review in Pharmaceutical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Mussa ArvaniMAestro Medical Solutions, Cologne, Germany. connect@maestroms.net.ORCID http://orcid.org/0009-0007-2808-7522

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Regulatory acceleration, expanded reliance on real-world evidence (RWE), and increasing integration of artificial intelligence (AI) into healthcare systems have substantially reshaped expectations placed on Medical Affairs. Accelerated and conditional approval pathways are progressively shifting confirmatory evidence generation into the post-marketing phase, while regulatory agencies have formalized frameworks for incorporating RWE into benefit-risk evaluation and lifecycle decision making. In parallel, healthcare systems are increasingly conceptualized as learning health systems in which routine-care data inform iterative improvement. This Leading Article proposes a conceptual but operationally applicable framework that positions Medical Affairs as a Strategic Enterprise Integrator, responsible for coordinating lifecycle evidence architecture, scientific exchange, insight translation, and governance across development and real-world settings. The framework is structured around four interdependent capability domains: lifecycle evidence architecture; scientific translation and insight management; cross-functional governance; and AI/data governance, including oversight of large language model (LLM)-supported workflows in medical information and analytics. The proposed model explicitly delineates interfaces with Clinical Development, Pharmacovigilance, Market Access/Health Economics and Outcomes Research, and Commercial functions to reduce redundancy while preserving functional accountability. Methodological considerations for RWE are anchored in principles of fit-for-purpose data, study design discipline, and transparent interpretation, while AI-enabled processes are addressed through a scientific governance lens emphasizing validation, auditability, and context-of-use. Illustrative operational examples and a staged maturity model with measurable indicators are introduced to support practical implementation. The framework positions Medical Affairs as a scientifically accountable integrator of lifecycle evidence within evolving regulatory science. As a conceptual model this framework requires further empirical validation to assess its applicability and generalizability across organizational contexts.

Indexed as

Artificial IntelligenceDelivery of Health CareHumansLarge Language ModelsPharmacovigilance

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.